Continue to support Medicare's ability to negotiate drug prices.

Suhas Subramanyam · Virginia · Democratic

policy impact 0.72 specificity 0.81 extraction confidence 95%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Occurrences

...and he will continue to support the ability of Medicare to negotiate drug prices.

Commits to supporting Medicare drug price negotiation.

Priorities — Suhas for Virginia
campaign · campaign_site · model gpt-5.4-mini

Evidence

unverified · Source version 11912 · locator unknown

"He fought for transparency in prescription drug pricing and won, and he will continue to support the ability of Medicare to negotiate drug prices. Suhas will stand up to Big Pharma and work to end the chronic disease epidemic."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Campaign issue page states Subramanyam previously fought for prescription drug price transparency and says he will continue to support Medicare drug-price negotiation.

unresolved same_term

Priorities — Suhas for Virginia
campaign · model gpt-5.4-mini · confidence 92%

unverified · Source version 20107 · locator unknown

"In the Virginia House of Delegates (2019-2023) and the Virginia State Senate (2023-2024), Suhas passed landmark legislation to lower the costs of tolls, utility bills, and prescription drugs."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official House site reflects an ongoing general record of lowering prescription drug costs, but it does not show a new Medicare drug-price negotiation action in the lookback window.

unresolved same_term

Representative Suhas Subramanyam |
primary · model gpt-5.4-mini · confidence 68%

unverified · Source version 61210 · locator unknown

SEC. 71203. EXPANDING AND CLARIFYING THE EXCLUSION FOR ORPHAN DRUGS UNDER THE DRUG PRICE NEGOTIATION PROGRAM.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official public law text shows H.R. 1 included a Medicare drug-price negotiation provision expanding and clarifying orphan-drug exclusions, a change relevant to Medicare's negotiation authority. This source establishes the policy context for Subramanyam's recorded vote but does not itself show fulfillment.

unresolved same_term

Public Law 119-21 - An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
secondary · model gpt-5.5 · confidence 90%

unverified · Source version 61212 · locator unknown

Vote Question: On Motion to Concur in the Senate Amendment One Big Beautiful Bill Act Vote Type: Recorded Vote Status: Passed

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The House Clerk records final House concurrence on H.R. 1. The same roll-call page records Subramanyam as voting No, documenting concrete in-office opposition to a bill that included changes expanding exclusions from the Medicare Drug Price Negotiation Program; because the bill passed, this is effort rather than full delivery.

partial same_term A for effort

Office of the Clerk, U.S. House of Representatives
secondary · model gpt-5.5 · confidence 88%

unverified · Source version 85123 · locator unknown

October 31, 2026 — Deadline for participating drug companies to accept or reject a final MFP offer from CMS.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official CMS guidance shows the current Medicare drug-price negotiation cycle remains pending past the 2026-10-06 to 2026-10-08 lookback window, with the next documented deadline on October 31, 2026. This does not prove a new Subramanyam action, so the campaign commitment remains unresolved based on new lookback research.

unresolved same_term

factsheet-medicare-negotiation-selected-drug-list-ipay-2028.pdf
secondary · model gpt-5.5 · confidence 74%

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): unresolved. unknown

The promise is to continue supporting Medicare drug-price negotiation in federal office. The supplied evidence shows a campaign position and a general biography about prior prescription-drug cost work, but it does not document a House vote, cosponsorship, bill sponsorship, oversight action, public in-office statement, or other material federal action by Subramanyam after taking office that preserved or expanded Medicare negotiation authority. Because he is still in office and the record provided does not establish either delivery or failure, the claim remains unresolved rather than delivered or never fulfilled.

provider codex_cli · model gpt-5.5 · confidence 78%